Effect of phlebotomy versus oral contraceptives containing cyproterone acetate on the clinical and biochemical parameters in women with polycystic ovary syndrome: a randomized controlled trial
article
OA: gold
CC0
Abstract
BACKGROUND: Reduction of the body iron stores can improve hyperandrogenemia and insulin resistance. This study aimed to compare clinical and para-clinical responses to the treatment of phlebotomy using oral contraceptive pills (OCs) containing cyproterone acetate in women with PCOS. METHODS: In this randomized clinical trial, 64 patients with PCOS were randomly assigned to the phlebotomy and OCs groups (n = 32 in each group). The intervention group, using a single treatment procedure, underwent venesection of 450 mL of whole blood at the early follicular phase of the spontaneous or progesterone-induced menstrual cycle. The control group received OCs pills for 3 months from the 1th day of spontaneous or progesterone-induced menstrual cycle onwards for 3 weeks, followed by a pill-free interval of 7 days. The women were evaluated after the 3-month intervention. The primary outcome measure was a change in the HOMA-IR and free androgen index (FAI). Secondary outcomes were changes in the Ferriman-Gallwey (FG) score and other clinical, biochemical and hormonal changes from the baseline (pre-treatment) to week 12. RESULTS: In the phlebotomy group, 27 (84.3%) and in the OCs group 30 (93.7%) of the women completed the 3-month follow-up. The median HOMA-IR significantly decreased from 3.5 to 2.7 in the phlebotomy, and from 3.1 to 2.8 in the OCs group, and the changes were comparable between the groups. Median changes in the FAI significantly decreased in both groups, but the differences were not statistically significant between the groups (P = 0.061). With regard to secondary outcomes, mean FG scores in both groups significantly decreased [from 16.8 (6) to 13.3 (7.4), P < 0.028] in the phlebotomy group and [from 14.3 (7) to 9.8 (7.6) in the OCs group, P = 0.001] after 3 months of treatment, but such changes had no statistically significant differences between the groups. During treatment, menstrual cycles became regular in all women in the OCs group and in 12.27 (44.4%) of the women in the phlebotomy group, and the difference was statistically significant (P = 0.001). Despite no statistically significant differences in lipid profiles between the groups at the baseline, triglycerides were significantly higher in the OCs group compared to the phlebotomy at end of follow up (p = 0.019). CONCLUSION: Both treatment modalities had similar beneficial effects on insulin resistance and on androgenic profiles. However, OCs was reported more effective in treating menstrual irregularities and phlebotomy had less adverse effects on triglyceride concentrations. TRIAL REGISTRATION: Code: IRCT2013080514277N1 .
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (46)
- doi:10.2337/dc07-0642 via openalex
- doi:10.1111/j.1572-0241.2007.01192.x via openalex
- doi:10.1182/blood.v89.3.739 via openalex
- doi:10.3109/09513590.2014.943725 via openalex
- doi:10.2337/diacare.25.12.2249 via openalex
- doi:10.1371/journal.pone.0003547 via openalex
- doi:10.1016/j.ejogrb.2013.09.029 via openalex
- doi:10.1210/jc.2007-2656 via openalex
- doi:10.1210/jc.2010-2211 via openalex
- doi:10.1016/s0015-0282(03)01188-9 via openalex
- doi:10.1210/er.2004-0004 via openalex
- doi:10.1186/1757-2215-7-18 via openalex
- doi:10.1016/j.jacc.2008.09.042 via openalex
- doi:10.1186/1741-7015-10-54 via openalex
- doi:10.1161/01.cir.103.1.52 via openalex
- doi:10.1016/j.molmet.2016.10.006 via openalex
- doi:10.1093/clinchem/33.8.1372 via openalex
- doi:10.2337/dc06-2625 via openalex
- doi:10.1210/jc.2014-3196 via openalex
- doi:10.2337/dc09-0420 via openalex
- doi:10.1016/j.tem.2012.04.003 via openalex
- doi:10.1007/s00404-010-1790-9 via openalex
- doi:10.1186/1476-511x-9-52 via openalex
- doi:10.1210/jcem.77.2.8345055 via openalex
- doi:10.3109/09513590.2015.1117069 via openalex
- doi:10.2337/diacare.28.8.2042 via openalex
- doi:10.1186/1477-7827-9-39 via openalex
- doi:10.1016/j.fertnstert.2003.10.004 via openalex
- doi:10.1111/cen.13477 via openalex
- doi:10.2147/oajc.s85543 via openalex
- doi:10.1080/13625187.2017.1317735 via openalex
- doi:10.1016/j.fertnstert.2017.09.004 via openalex
- doi:10.1111/cen.13389 via openalex
- doi:10.2147/clep.s37559 via openalex
- doi:10.2337/dc07-0939 via openalex
- doi:10.1111/j.1365-2265.2012.04466.x via openalex
- doi:10.1210/jc.2006-1864 via openalex
- doi:10.1007/s40618-017-0650-x via openalex
- doi:10.1080/1354750x.2019.1620335 via openalex
- doi:10.2337/diabetes.51.4.1000 via openalex
- doi:10.1038/ijo.2008.154 via openalex
- doi:10.1210/jc.2002-030024 via openalex
- doi:10.1186/1741-7015-10-119 via openalex
- doi:10.1371/journal.pone.0168402 via openalex
- doi:10.1007/s00125-012-2633-y via openalex
- doi:10.1016/0026-0495(94)90204-6 via openalex
Source provenance
- openalex
- last seen: 2026-05-14T06:03:08.038466+00:00
License: CC0
· commercial use OK